PHP
DAWN

Parkman Healthcare Partners’s Day One Biopharmaceuticals DAWN Stock Holding History

Parkman Healthcare Partners’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-645,544
Closed -$6.02M – 97
2025
Q4 		$6.02M Buy
645,544
+343,798
+114% +$2.87M 0.57% 54
2025
Q3 		$2.13M Sell
301,746
-198,254
-40% -$1.36M 0.22% 80
2025
Q2 		$3.25M Sell
500,000
-543,162
-52% -$3.74M 0.37% 70
2025
Q1 		$8.27M Buy
1,043,162
+42,688
+4% +$460K 0.98% 38
2024
Q4 		$12.7M Buy
1,000,474
+76,334
+8% +$1.06M 1.69% 21
2024
Q3 		$12.9M Buy
924,140
+15,318
+2% +$219K 1.64% 21
2024
Q2 		$12.5M Buy
908,822
+217,010
+31% +$3.18M 1.68% 18
2024
Q1 		$11.4M Buy
691,812
+66,063
+11% +$989K 1.4% 27
2023
Q4 		$9.14M Buy
625,749
+159,341
+34% +$1.93M 1.29% 26
2023
Q3 		$5.72M Buy
466,408
+38,129
+9% +$497K 1.05% 31
2023
Q2 		$5.11M Buy
428,279
+28,059
+7% +$366K 0.89% 35
2023
Q1 		$5.35M Buy
400,220
+175,737
+78% +$3.43M 1.16% 34
2022
Q4 		$4.83M Buy
224,483
+12,292
+6% +$252K 1.29% 28
2022
Q3 		$4.25M Buy
212,191
+97,441
+85% +$2.07M 1.21% 26
2022
Q2 		$2.05M Buy
+114,750
New +$1.18M 0.76% 43

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Parkman Healthcare Partners's DAWN Position: Q1 2026 in Review

Parkman Healthcare Partners sold out of Day One Biopharmaceuticals (DAWN) in Q1 2026, closing a stake of 645,544 shares — an estimated $6.02M sold.

Parkman Healthcare Partners first reported a position in DAWN in Q2 2022 and held it in 15 quarters. The position peaked at $12.9M in Q3 2024. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Parkman Healthcare Partners reported no remaining Day One Biopharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Parkman Healthcare Partners sold 645,544 Day One Biopharmaceuticals shares in Q1 2026, an estimated $6.02M.
  • Parkman Healthcare Partners first reported a position in Day One Biopharmaceuticals in Q2 2022 and held it in 15 quarters.
  • Parkman Healthcare Partners's Day One Biopharmaceuticals position peaked at $12.9M in Q3 2024.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.